Key result
Cardiology ordering strongly predicted CCTA over SPECT use, whereas the post-2021 guideline period alone did not.
Why the study?
Although the 2021 Chest Pain Guideline strongly recommended CCTA as a first-line test for stable chest pain without known coronary artery disease, real-world adoption remains variable and changes in CCTA versus SPECT utilization within the Military Health System required evaluation.
Does publication of the 2021 Chest Pain Guideline and ordering provider specialty affect the utilization of CCTA versus SPECT in patients evaluated for suspected coronary artery disease?
Cohort (n=15,772)
No
Does publication of the 2021 Chest Pain Guideline and ordering provider specialty affect the utilization of CCTA versus SPECT in patients evaluated for suspected coronary artery disease?
Answers are grounded in this paper and cite their sources.
Publication of the 2021 Chest Pain Guideline did not uniformly increase CCTA adoption at a large military medical center, as ordering specialty remained the dominant driver of modality selection with diverging utilization between cardiologists and non-cardiologists.
INTRODUCTION: Coronary computed tomography angiography (CCTA) received a strong recommendation in the 2021 Chest Pain Guideline as a first-line test for the evaluation of stable chest pain in patients without known coronary artery disease; however, real-world adoption remains variable. Within the Military Health System, imaging decisions directly affect operational readiness. We evaluated changes in the utilization of CCTA versus single-photon emission computed tomography (SPECT) myocardial perfusion imaging before and after guideline publication at a large military medical center. MATERIALS AND METHODS: We conducted a retrospective cohort study of 15,772 CCTA or SPECT studies performed for the evaluation of suspected coronary artery disease from 2018 through 2023 at Joint Base San Antonio. Studies were stratified into pre-guideline (on or before October 31, 2021) and post-guideline (on or after November 1, 2021) periods. The primary outcome was imaging modality (CCTA versus SPECT), analyzed by ordering specialty, sex, and age. Chi-square testing, repeat-testing characterization, and generalized estimating equations logistic regression were performed. RESULTS: Overall, 41.3% of studies were CCTA and 58.7% were SPECT. Among cardiologists, the proportion of CCTA studies increased from 50% to 61% after guideline publication, whereas CCTA use among non-cardiology specialties declined from 36% to 25%, reaching a quarterly nadir of 12.6% in quarter 2 of 2022. Cardiology ordering was the strongest independent predictor of CCTA use (odds ratio 1.90, 95% CI, 1.76-2.05; P < .001). The post-guideline period alone was not independently associated with increased CCTA use (odds ratio 0.98, P = .69). Younger age strongly favored CCTA, and repeat testing most commonly involved SPECT-to-SPECT sequences. CONCLUSIONS: Publication of the 2021 Chest Pain Guideline was not associated with a uniform increase in CCTA adoption. Provider specialty, rather than the guideline period itself, was the dominant factor associated with modality selection, highlighting the need for targeted education and decision-support interventions to improve evidence-based imaging utilization.
No takes yet. Share an insight, caveat, or question.
Soderstrom et al. (2026) conducted a cohort in Suspected coronary artery disease (n=15,772). Cardiology ordering vs non-cardiology ordering (and post-2021 Chest Pain Guideline period) vs. Non-cardiology ordering (and pre-guideline period on or before October 31, 2021) was evaluated on Imaging modality selection (CCTA versus SPECT) (OR 1.90, 95% CI 1.76-2.05, p=<0.001). Cardiology ordering strongly predicted CCTA over SPECT use, whereas the post-2021 guideline period alone did not.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: